Table 2 Disease-free survival events: pCR versus non-pCR patients.

From: Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab

 

Overall population (n = 526)

MSKCC HER2-status (n = 130)

 

pCR n = 286

non-pCR n = 240

pCR Tot: 77

non-pCR Tot: 53

DFS events

14

22

8

5

Locoregional recurrence

4

3

4

0

 Breast

1

2

1

—

 Regional lymph nodes

2

—

2

—

 DCIS

1

1

1

—

Distant recurrence

9

17

4

5

 Brain only

7

5

3

2

 Visceral disease

1

7

1

2

 Non-visceral disease

1

5

0

1

Death*

1

2

0

0

  1. *death without prior recurrence events.
  2. pCR pathological complete response, DCIS ductal carcinoma in situ.
Back to article page